此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

2026年9月4日 更新者：JCR Pharmaceuticals Co., Ltd.

A Global, Open-Label, Phase I/II Trial, to Evaluate Safety, Tolerability, Pharmacodynamic and Preliminary Efficacy of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

This is a global, open-label, Phase I/II, interventional trial in participants younger than 6 years of age with Mucopolysaccharidosis Type IIIB (MPS IIIB), designed to assess the safety and tolerability of JR-446, determine its pharmacodynamic effects, and explore its potential to demonstrate early clinical effects on disease-relevant outcomes.

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

介入性

注册 (估计的)

12

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 德国
      • Hamburg、德国、20246
        • University Medical Center Hamburg-Eppendorf
        • 接触：
          • Nicole Maria Muschol
          • 电话号码：+49 (0) 40 7410 53714
          • 邮箱：muschol@uke.de
  • 美国
    • California
      • Oakland、California、美国、94609
        • Children's Hospital Oakland Research Institution, Attn: 2900 Wing
        • 接触：
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15224
        • UPMC Children's Hospital of Pittsburgh
        • 接触：
    • Virginia
      • Fairfax、Virginia、美国、22030
        • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
        • 接触：
  • 英国
      • London、英国、WC1N 3JH
        • Great Ormond Street Hospital for Children
        • 接触：

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Patients with confirmed MPS IIIB with a phenotype of MPS IIIB that is not classified as slowly progressive (i.e., not attenuated).
  2. A chronological age <6 years.
  3. Ability to complete and achieve a Standard score ≥55, using either Bailey Scale of Infant Development-4 (BSID-4) Cognitive domain or Kaufman Assessment Battery for Children-II (KABC-II) Non-Verbal Index, whichever tool is most appropriate for the participant's chronological age.

Exclusion Criteria:

  1. Contraindication for lumbar puncture or MRI.
  2. A participant who has a medical condition or extenuating circumstance that, in the opinion of the principal investigator or sub-investigator, might compromise the participant's ability to comply with protocol requirements, the participant's well-being or safety, or the interpretability of the participant's clinical data.
  3. A participant who has received any other investigational drug product (including but not limited to, tralesinidase alfa enzyme replacement therapy [TA-ERT], Genistein, KINERET [anakinra], ambroxol, miglustat) within 4 months (or 5 half-lives, whichever is longer) before the time of providing informed consent.
  4. A participant who has received gene therapy treatment or hematopoietic stem cell transplantation (HSCT) with successful engraftment.
  5. Serious drug allergy or hypersensitivity to any components of JR-446 or medications likely prescribed during the trial.
  6. A participant has a history of bleeding disorder or current use of medications that, in the opinion of the investigator, place them at risk of bleeding following lumbar puncture.
  7. A patient with recurrent epileptic seizures not adequately controlled with anti-seizure medication, and which, in the clinical judgment of the principal investigator, would preclude safe participation in the trial.
  8. Serology consistent with human immunodeficiency virus (HIV) exposure or consistent with active hepatitis B (HepB) or hepatitis C (HepC) infection.
  9. A participant/family, who, in the opinion of the investigator, may not be able to comply with protocol requirements and cooperate fully with the trial assessments, procedures, and scheduling for JR-446 IMP dose administrations.
  10. Study participants for whom informed consent is unable to be provided by a parent or legal guardian; or when applicable for a study participant who is unable to provide assent with respect to study participation in conjunction with parental or legal guardian consent for participation on study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：JR-446
Arm: 1
药品：JR-446
静脉输液

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
To establish the safety and tolerability of JR-446 in MPS IIIB patients following repeated dose administration
大体时间：Up to 1 year (multiple visits)
Incidence and severity of treatment-emergent adverse events; Incidence and severity of infusion-associated reactions; Incidence of clinically significant changes/abnormalities in safety laboratory tests, vital signs, and electrocardiogram.
Up to 1 year (multiple visits)

次要结果测量

结果测量
大体时间
Change From Baseline in Cerebrospinal Fluid Heparan Sulfate Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Absolute Change From Baseline in Serum Heparan Sulfate Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Percent Change From Baseline in Serum Heparan Sulfate Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Absolute Change From Baseline in Urine Heparan Sulfate Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Percent Change From Baseline in Urine Heparan Sulfate Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Absolute Change From Baseline in Serum Neurofilament Light Chain Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Percent Change From Baseline in Serum Neurofilament Light Chain Concentration
大体时间：Through Week 53 (up to 1 year; multiple visits)
Through Week 53 (up to 1 year; multiple visits)
Change in Cognitive Function Assessments From Baseline
大体时间：Through Week 53 (up to 1 year)
Through Week 53 (up to 1 year)
Change in Brain MRIs From Baseline
大体时间：Through Week 53 (up to 1 year)
Through Week 53 (up to 1 year)
Change in Height Standard Deviation Score (SDS) From Baseline (using WHO child growth standards)
大体时间：Through Week 53 (up to 1 year)
Through Week 53 (up to 1 year)
Change in Weight SDS From Baseline (using WHO child growth standards)
大体时间：Through Week 53 (up to 1 year)
Through Week 53 (up to 1 year)
Change in Body Mass Index (BMI) SDS From Baseline (using WHO child growth standards)
大体时间：Through Week 53 (up to 1 year)
Through Week 53 (up to 1 year)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

JCR Pharmaceuticals Co., Ltd.

合作者

MEDIPAL HOLDINGS CORPORATION

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月9日

初级完成 (估计的)

2028年6月30日

研究完成 (估计的)

2028年9月30日

研究注册日期

首次提交

2026年5月14日

首先提交符合 QC 标准的

2026年6月8日

首次发布 (实际的)

2026年6月11日

研究记录更新

最后更新发布 (实际的)

2026年9月8日

上次提交的符合 QC 标准的更新

2026年9月4日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • JR-446-201

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅